(2E,4E,6E)-7-(7-heptoxy-4,4-dimethyl-1,1-dioxo-2,3-dihydrothiochromen-6-yl)-3-methylocta-2,4,6-trienoic acid | 153049-51-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (2E,4E,6E)-7-(7-heptoxy-4,4-dimethyl-1,1-dioxo-2,3-dihydrothiochromen-6-yl)-3-methylocta-2,4,6-trienoic acid
• CAS: 153049-51-5
• 化学式: C₂₇H₃₈O₅S
• 分子量: 474.7
• InChiKey: DAQXGPCMSTXZBM-BAKLMJQHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.8
• 重原子数：
  33
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  89
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
  申请人：IO Therapeutics, Inc.

  公开号：US10485775B2

  公开（公告）日：2019-11-26

  Disclosed herein are methods for culturing CAR-modified immune cells with at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.

  本文公开了用至少一种维甲酸受体和/或维甲酸 X 受体活性剂培养 CAR 修饰免疫细胞的方法。
• Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
  申请人：Io Therapeutics, Inc.

  公开号：US10874627B2

  公开（公告）日：2020-12-29

  Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.

  本文公开了治疗癌症的方法，包括给药 CAR 修饰的免疫细胞和至少一种视黄酸受体和/或视黄醇 X 受体活性剂。
• RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY
  申请人：Io Therapeutics, Inc.

  公开号：US20190282524A1

  公开（公告）日：2019-09-19

  Disclosed herein are methods for culturing CAR-modified immune cells with at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
• IMMUNOMODULATORY AND DIFFERENTIATING FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY
  申请人：Io Therapeutics, Inc.

  公开号：US20200069622A1

  公开（公告）日：2020-03-05

  Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.